Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > REGULATORY
REGULATORY
- New Flu Act to Take Effect on April 13
April 11, 2013
- Japan Launches Strategic Fund for Drug R&D in Developing World
April 10, 2013
- MHLW Issues Order for Improvement to 5 Generic Companies due to GMP Violations by South Korean Supplier
April 9, 2013
- MHLW Unveils Generic Roadmap, Aims for 60%-Share by FY2017
April 8, 2013
- Expert Council on Cancer Research of MHLW, MEXT, METI to Hold 1st Meeting on April 15 to Discuss Future Cancer Research Strategy
April 8, 2013
- Eisai’s HTA-Savvy Tsuchiya Picked as CSIMC Expert Member
April 5, 2013
- FPMAJ Calls for PAL Amendment to Allow Applications Based on Information in Public Domain for Ultra-Orphan Drugs
April 5, 2013
- HIB Director-General Kikura Calls for Discussions on Pricing Rules for Combination Products Containing OTC Drugs
April 5, 2013
- Astem Pres. Yoshimura Says Wholesalers Should Break Away from Dependence on Long-Listed Drugs
April 4, 2013
- Prime Minister Abe Asks Ministries to Begin Discussions Toward Establishing Japanese Version of NIH
April 2, 2013
- Hodanren Calls for Inclusion of Pharmacies’ Technical Fees in Domestic Drug Prices When Comparing Drug Prices in Japan, US, and Europe
April 1, 2013
- MOF Budget Examiner Hirotsugu Shinkawa Hopes to See New Generic Target Set at Highest Share Achievable at Fastest Pace
March 29, 2013
- MHLW’s Generic Roadmap Compilation in Homestretch
March 29, 2013
- MHLW Committee Calls for New Name for Norvasc or Nolvadex to Prevent Further Prescribing Errors
March 29, 2013
- PFSB Notification Calls for Revisions of Precautions for Gabapentin, Other Drugs
March 28, 2013
- MHLW to Request Development of 2 Unapproved Indications Determined to Have Unmet Medical Needs
March 27, 2013
- PAFSC Committee Approves Reclassification of Tiquizium Bromide and Diclofenac as Class 2 OTC Drugs
March 26, 2013
- Administrative Evaluation: Health Ministry Urged to Review All-Specification Listing Requirement for Generics
March 25, 2013
- LDP Subcommittee Begins Discussions on Amending PAL; Bill Expected to Be Submitted During Current Diet Session
March 25, 2013
- Regulatory Reform Council Not Convinced of MHLW’s Response to Online Sale of OTC Drugs
March 25, 2013
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…